Pfizer Announces Results Of OPT Compare Phase 3 Study Of Tofacitinib

(RTTNews) - Pfizer Inc. (NYSE:PFE) announced detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were previously announced in October 2013.

The results of OPT Compare showed that in a step-down procedure design, tofacitinib 10 mg twice daily (BID) was non-inferior to high-dose ENBREL (etanercept) 50 mg twice weekly (BIW), and tofacitinib 5 mg twice daily did not meet the non-inferiority criteria compared to high-dose ENBREL. No new safety signals for tofacitinib were observed in the OPT Compare study.

The detailed OPT Compare study results mark the completion of the first Phase 3 trial for tofacitinib in psoriasis.